PL377479A1 - Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu - Google Patents

Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu

Info

Publication number
PL377479A1
PL377479A1 PL377479A PL37747903A PL377479A1 PL 377479 A1 PL377479 A1 PL 377479A1 PL 377479 A PL377479 A PL 377479A PL 37747903 A PL37747903 A PL 37747903A PL 377479 A1 PL377479 A1 PL 377479A1
Authority
PL
Poland
Prior art keywords
release
controlled
active substance
high fat
fat environment
Prior art date
Application number
PL377479A
Other languages
English (en)
Polish (pl)
Inventor
Mark Brian Chidlaw
Dwayne Thomas Friesen
Scott Max Herbig
James Alan Schriver Nightingale
Cynthia Ann Oksanen
James Blair West
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL377479A1 publication Critical patent/PL377479A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377479A 2002-12-11 2003-11-28 Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu PL377479A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43286002P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
PL377479A1 true PL377479A1 (pl) 2006-02-06

Family

ID=32508002

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377479A PL377479A1 (pl) 2002-12-11 2003-11-28 Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu

Country Status (18)

Country Link
US (1) US20040121015A1 (https=)
EP (1) EP1572163A1 (https=)
JP (1) JP2006510655A (https=)
KR (1) KR20050088311A (https=)
CN (1) CN1726012A (https=)
AR (1) AR042340A1 (https=)
AU (1) AU2003283688A1 (https=)
BR (1) BR0317275A (https=)
CA (1) CA2508722A1 (https=)
CO (1) CO5570656A2 (https=)
MX (1) MXPA05005812A (https=)
NO (1) NO20053068L (https=)
NZ (1) NZ539915A (https=)
PL (1) PL377479A1 (https=)
RU (1) RU2308263C2 (https=)
TW (1) TWI257302B (https=)
WO (1) WO2004052343A1 (https=)
ZA (1) ZA200503812B (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
JP2008528567A (ja) * 2005-01-28 2008-07-31 ファイザー・プロダクツ・インク 速崩壊性の微孔性結合剤
WO2006123357A2 (en) * 2005-02-22 2006-11-23 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
ATE481096T1 (de) * 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2007028035A2 (en) 2005-09-01 2007-03-08 Proteus Biomedical, Inc. Implantable zero-wire communications system
US8956287B2 (en) 2006-05-02 2015-02-17 Proteus Digital Health, Inc. Patient customized therapeutic regimens
US8054140B2 (en) 2006-10-17 2011-11-08 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
SG175681A1 (en) 2006-10-25 2011-11-28 Proteus Biomedical Inc Controlled activation ingestible identifier
US8718193B2 (en) 2006-11-20 2014-05-06 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
EP3785599B1 (en) 2007-02-01 2022-08-03 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker systems
WO2008101107A1 (en) 2007-02-14 2008-08-21 Proteus Biomedical, Inc. In-body power source having high surface area electrode
WO2008112577A1 (en) 2007-03-09 2008-09-18 Proteus Biomedical, Inc. In-body device having a multi-directional transmitter
EP2063771A1 (en) 2007-03-09 2009-06-03 Proteus Biomedical, Inc. In-body device having a deployable antenna
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
DK2215726T3 (en) 2007-11-27 2018-04-09 Proteus Digital Health Inc Transbody communication modules with communication channels
EP3235491B1 (en) 2008-03-05 2020-11-04 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems
EP2313002B1 (en) 2008-07-08 2018-08-29 Proteus Digital Health, Inc. Ingestible event marker data framework
CN102176862B (zh) 2008-08-13 2014-10-22 普罗透斯数字保健公司 可摄入电路
PE20110543A1 (es) 2008-08-15 2011-08-04 Ironwood Pharmaceuticals Inc Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
EP2349445A4 (en) * 2008-11-13 2012-05-23 Proteus Biomedical Inc INTAKEABLE THERAPEUTIC ACTIVATION SYSTEM AND METHOD
CA2746650A1 (en) * 2008-12-11 2010-06-17 Proteus Biomedical, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
TWI424832B (zh) 2008-12-15 2014-02-01 波提亞斯數位康健公司 與身體有關的接收器及其方法
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
JP2012514799A (ja) 2009-01-06 2012-06-28 プロテウス バイオメディカル インコーポレイテッド 摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム
SG172847A1 (en) 2009-01-06 2011-08-29 Proteus Biomedical Inc Pharmaceutical dosages delivery system
GB2480965B (en) 2009-03-25 2014-10-08 Proteus Digital Health Inc Probablistic pharmacokinetic and pharmacodynamic modeling
WO2010129288A2 (en) 2009-04-28 2010-11-11 Proteus Biomedical, Inc. Highly reliable ingestible event markers and methods for using the same
EP2432458A4 (en) 2009-05-12 2014-02-12 Proteus Digital Health Inc ACCEPTABLE EVENT MARKER WITH SUGAR COMPONENT
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
EP2467707A4 (en) 2009-08-21 2014-12-17 Proteus Digital Health Inc DEVICE AND METHOD FOR MEASURING BIOLOGICAL PARAMETERS
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
UA109424C2 (uk) 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
EP2531099B1 (en) 2010-02-01 2018-12-12 Proteus Digital Health, Inc. Data gathering system
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
CN102905672B (zh) 2010-04-07 2016-08-17 普罗秋斯数字健康公司 微型可吞服装置
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
EP2603232B1 (en) 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP2642983A4 (en) 2010-11-22 2014-03-12 Proteus Digital Health Inc DEVICE INGREABLE WITH PHARMACEUTICAL PRODUCT
JP2014514032A (ja) 2011-03-11 2014-06-19 プロテウス デジタル ヘルス， インコーポレイテッド 様々な物理的構成を備えた着用式個人身体関連装置
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
KR101898964B1 (ko) 2011-07-21 2018-09-14 프로테우스 디지털 헬스, 인코포레이티드 모바일 통신 장치, 시스템, 및 방법
MX347354B (es) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
CN104487347B (zh) 2012-07-23 2017-09-01 普罗秋斯数字健康公司 用于制造包括电子器件的片剂的方法和系统
CA2888871C (en) 2012-10-18 2016-08-09 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
WO2014120669A1 (en) 2013-01-29 2014-08-07 Proteus Digital Health, Inc. Highly-swellable polymeric films and compositions comprising the same
JP6498177B2 (ja) 2013-03-15 2019-04-10 プロテウス デジタル ヘルス， インコーポレイテッド 本人認証装置システムおよび方法
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス， インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
RU2736776C2 (ru) 2013-09-20 2020-11-20 Протеус Диджитал Хелс, Инк. Способы, устройства и системы приема и декодирования сигналов в присутствии шума с использованием срезов и деформирования
JP2016537924A (ja) 2013-09-24 2016-12-01 プロテウス デジタル ヘルス， インコーポレイテッド 事前に正確に把握されていない周波数において受信された電磁信号に関する使用のための方法および装置
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
CN109843149B (zh) 2016-07-22 2020-07-07 普罗秋斯数字健康公司 可摄入事件标记的电磁感测和检测
US10820831B2 (en) 2016-10-26 2020-11-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
CN111214456A (zh) * 2020-03-10 2020-06-02 浙江普利药业有限公司 伏立康唑干混悬剂及其制备方法
CR20230109A (es) * 2020-07-30 2023-05-11 Faes Farma Sa Sistema de liberación de fármacos descongestivos y bilastina
CN112198274B (zh) * 2020-11-02 2022-04-05 北京市理化分析测试中心 一种检测氨酚伪麻片中盐酸伪麻黄碱的方法
CN113514579A (zh) * 2021-06-23 2021-10-19 远大生命科学(武汉)有限公司 一种依托咪酯乳状注射液体外释放曲线的测定方法
CN115647000B (zh) * 2022-10-26 2025-06-27 华能阜新风力发电有限责任公司 一种基于低温热解的风电叶片回收方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
WO1993019739A1 (en) * 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
CA2261787C (en) * 1997-05-30 2006-11-14 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Also Published As

Publication number Publication date
MXPA05005812A (es) 2005-08-16
CO5570656A2 (es) 2005-10-31
BR0317275A (pt) 2005-11-08
TW200425888A (en) 2004-12-01
TWI257302B (en) 2006-07-01
NO20053068L (no) 2005-09-07
EP1572163A1 (en) 2005-09-14
US20040121015A1 (en) 2004-06-24
RU2308263C2 (ru) 2007-10-20
ZA200503812B (en) 2006-07-26
CA2508722A1 (en) 2004-06-24
NO20053068D0 (no) 2005-06-22
KR20050088311A (ko) 2005-09-05
RU2005118101A (ru) 2006-01-20
CN1726012A (zh) 2006-01-25
JP2006510655A (ja) 2006-03-30
AU2003283688A1 (en) 2004-06-30
WO2004052343A1 (en) 2004-06-24
NZ539915A (en) 2007-09-28
AR042340A1 (es) 2005-06-15

Similar Documents

Publication Publication Date Title
PL377479A1 (pl) Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu
PT1517609E (pt) Combinações de substâncias activas fungicidas
PL374390A1 (en) Fungicidal active substance combinations
AU2003252299A8 (en) Novel physiologically active substance
SI1608362T1 (sl) Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
AU2003267255A8 (en) Methods and devices for active bioassay
PT1362582E (pt) Forma de dosagem sólida revestida
NO20042367L (no) Mikronisert filmdannende pulver omfattende et aktivt stoff
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
AU2003238179A8 (en) Herbicidally active heterocyclylalkynes
EP1590144A4 (en) PROCESS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE FORMULATIONS
GB0212143D0 (en) Processor Monitor
AU2003260721A1 (en) Fish enclosure
GB0205347D0 (en) Biologically active complex
AUPS015802A0 (en) Fumigant formulation
AU2003209930A1 (en) Downloading of software programs
HU0303383D0 (en) Pellets containing active ingredient
GB0219897D0 (en) Pharmaceutically active compounds
ZA200508282B (en) Method of preparing a formulation containing a microdosed active principle
AU2003300696A8 (en) Chemoenzymatically hydrolysable biologically active compounds
GB0219893D0 (en) Pharmaceutically active compounds
SI1517609T1 (sl) Fungicidne kombinacije učinkovin
TW555097U (en) Improved structure of wireless mouse housing
GB0219335D0 (en) Bait capsules

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)